0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Sign in

Purchase Options

• Subscribe to the journal

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA
Original Investigation  | 
Antiplatelet Therapy Duration Following Bare Metal or Drug-Eluting Coronary Stents:  The Dual Antiplatelet Therapy Randomized Clinical Trial
Dean J. Kereiakes, MD; Robert W. Yeh, MD; Joseph M. Massaro, PhD; et al.
JAMA
Editorial  | 
Can BRIGHT Restore the Glow of Bivalirudin?
Matthew A. Cavender, MD, MPH; David P. Faxon, MD
JAMA
Original Investigation  | 
Bivalirudin vs Heparin With or Without Tirofiban During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction:  The BRIGHT Randomized Clinical Trial
Yaling Han, MD, PhD; Jincheng Guo, MD; Yang Zheng, MD; et al.
JAMA Internal Medicine
Research Letter  | 
Population Trends in Rates of Coronary Revascularization
Robert W. Yeh, MD, MSc; Laura Mauri, MD, MSc; Robert E. Wolf, MS; et al.